BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/26/2014 5:16:00 PM | Browse: 1062 | Download: 1489
 |
Received |
|
2013-11-22 07:11 |
 |
Peer-Review Started |
|
2013-11-22 11:18 |
 |
To Make the First Decision |
|
2014-01-09 16:21 |
 |
Return for Revision |
|
2014-01-12 17:51 |
 |
Revised |
|
2014-02-13 02:42 |
 |
Second Decision |
|
2014-03-19 13:57 |
 |
Accepted by Journal Editor-in-Chief |
|
|
 |
Accepted by Executive Editor-in-Chief |
|
2014-03-19 14:58 |
 |
Articles in Press |
|
|
 |
Publication Fee Transferred |
|
|
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
2014-05-09 10:37 |
 |
Publish the Manuscript Online |
|
2014-05-28 11:45 |
Category |
Oncology |
Manuscript Type |
Topic Highlights |
Article Title |
Should capecitabine replace 5-fluorouracil in the first-line treatment of metastatic colorectal cancer?
|
Manuscript Source |
Invited Manuscript |
All Author List |
Carlos Aguado, Beatriz García-Paredes, Miguel Jhonatan Sotelo, Javier Sastre and Eduardo Díaz-Rubio |
Funding Agency and Grant Number |
|
Corresponding Author |
Eduardo Díaz-Rubio, MD, PhD, Department of Medical Oncology, Hospital Clínico San Carlos, Universidad Complutense de Madrid, Martín Lagos, s/n, 28040 Madrid, Spain. ediazrubio.hcsc@salud.madrid.org |
Key Words |
Capecitabine; 5-Fluorouracil; Metastatic colorectal cancer |
Core Tip |
Although there is still controversy about whether capecitabine-based regimes can replace 5-fluorouracil (5-FU) in clinical practice in the treatment of first-line metastatic colon cancer, we have reviewed most of different randomized studies and meta-analyses, and we can conclude that capecitabine appear to be an effective, safe, convenient, and economically viable alternative to 5-FU. |
Publish Date |
2014-05-28 11:45 |
Citation |
Aguado C, García-Paredes B, Sotelo MJ, Sastre J, Díaz-Rubio E. Should capecitabine replace 5-fluorouracil in the first-line treatment of metastatic colorectal cancer? World J Gastroenterol 2014; 20(20): 6092-6101 |
URL |
http://www.wjgnet.com/1007-9327/full/v20/i20/6092.htm |
DOI |
http://dx.doi.org/10.3748/wjg.v20.i20.6092 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345